$BMRN Recent News BioMarin shares rally as FDA mutes

New Post Public Reply Private Reply Replies (0) Message Board

Dec 16, 2013 at 2:42 PM

$BMRN Recent News

BioMarin shares rally as FDA mutes criticism of rare disorder drug 5:25 p.m. Nov. 15, 2013 - Russ Britt
German DAX ends at record as Europe stocks rally 11:10 a.m. Sept. 19, 2013 - Sara Sjolin
BioMarin rallies 7.6% on Roche takeover report 5:30 a.m. Sept. 19, 2013 - Sara Sjolin
S&P 500 retests the 50-day moving average 10:07 a.m. Sept. 9, 2013 - Michael Ashbaugh
Biotech ETF's breakout: bullish for stocks overall? 12:11 p.m. Sept. 5, 2013 - blogs.marketwatch.com
Acura, BioMarin mount independent rallies on their own positive news 2:28 p.m. July 1, 2013 - Russ Britt
After the close: Biogen slips, Epizyme slows, BioMarin stalls 4:57 p.m. June 4, 2013 - Russ Britt
Lofty expectations hit BioMarin in development of new cancer drugs 11:56 a.m. June 3, 2013 - Russ Britt
Get out of junk stocks now 12:14 p.m. March 22, 2013 - Mark Hulbert
Charting a slow-motion test of the 2012 peak 11:39 a.m. Jan. 11, 2013 - Michael Ashbaugh
U.S. benchmarks sustain the 2013 breakout 12:00 p.m. Jan. 4, 2013 - Michael Ashbaugh
Meet the S&P 500’s new range 11:17 a.m. Dec. 13, 2012 - Michael Ashbaugh
Charting a lackluster recovery attempt 11:49 a.m. Nov. 21, 2012 - Michael Ashbaugh
‘Aggressive’ comment hits Express Scripts 6:03 p.m. Nov. 5, 2012 - Russ Britt
BioMarin's GALNS meets primary endpoint in trial 9:24 a.m. Nov. 5, 2012 - MarketWatch.com
Biomarin says trial results meet primary endpoint 7:23 a.m. Nov. 5, 2012 - Greg Morcroft
Biomarin says its GALNS Phase III trial posiitve 7:23 a.m. Nov. 5, 2012 - Greg Morcroft
Staking out major support 9:46 a.m. Oct. 3, 2012 - Michael Ashbaugh
Corrective bounce, or sustainable upturn? 10:51 a.m. July 13, 2012 - Michael Ashbaugh
Bears come to life on jobs report 9:14 a.m. July 6, 2012 - Michael Ashbaugh

Insider Trading Alert - GNW, WFC, LII, WDR And BMRN Traded By Insiders 10:30 a.m. Dec. 12, 2013 - TheStreet.com
Orphan Drug Designations: Why You Should Care 10:23 a.m. Dec. 12, 2013 - Seeking Alpha
Myriad, Janssen Partner on BRACAnalysis - Analyst Blog 6:26 p.m. Dec. 10, 2013 - Zacks.com
Cramer's Lightning Round - The Quintessential American Stock That Is Going To Work (12/9/13) 6:01 a.m. Dec. 10, 2013 - Seeking Alpha
'Mad Money' Lightning Round: Get Serious on Sirius 6:00 a.m. Dec. 10, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: The Rally Rules 8:20 p.m. Dec. 9, 2013 - TheStreet.com
BioMarin Seeks Canadian Approval - Analyst Blog 11:50 a.m. Dec. 5, 2013 - Zacks.com
BioMarin Submits VIMIZIM(TM) (elosulfase alfa) NDS to Health Canada for the Treatment of Morquio A Syndrome Under Priority Review Status 8:00 a.m. Dec. 4, 2013 - CNW Group
BioMarin Pharmaceutical's Management Presents at 2013 Deutsche Bank BioFEST Conference (Transcript) 2:20 p.m. Dec. 3, 2013 - Seeking Alpha
Galena: A Pipeline Rich For Investors 2:46 a.m. Dec. 2, 2013 - Seeking Alpha
Biomarin Pharmaceutical Inc. Stock Upgraded (BMRN) 10:12 a.m. Nov. 29, 2013 - TheStreet.com
UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns 10:10 a.m. Nov. 27, 2013 - benzinga.com
Biotech Stock Roundup: EU News Boosts Biogen, Gilead & Celgene - Analyst Blog 10:01 a.m. Nov. 27, 2013 - Zacks.com
2014 FDA Drug Approval Decision Calendar 8:00 a.m. Nov. 27, 2013 - TheStreet.com
UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook 6:50 a.m. Nov. 27, 2013 - benzinga.com
Myriad, BioMarin Collaborate Again - Analyst Blog 5:05 p.m. Nov. 22, 2013 - Zacks.com
Amicus' 'Transformative" Changes Look More Like Big Step Backward 7:37 p.m. Nov. 20, 2013 - TheStreet.com
Jim Cramer's 6 Stocks in 60 Seconds: DKS COG WDAY BMRN DWRE TSLA (Update 1) 5:09 p.m. Nov. 20, 2013 - TheStreet.com
BioMarin Pharmaceutical Larger Than S&P 500 Component Linear Technology 4:44 p.m. Nov. 20, 2013 - TheStreet.com
Analysts: BioMarin Will Trade Up on Panel Vote and 3 More Research Notes to Browse 3:02 p.m. Nov. 20, 2013 - Wall St. Cheat Sheet

Reports, Positive Results, Updated Clinical Safety and Efficacy Data by Healthcare Companies - Research Report on Johnson & Johnson, Merck, BioMarin, Array BioPharma, and Brookdale Senior Living 8:00 a.m. Dec. 12, 2013 - PR Newswire
Daily Trends Scanner: BioMarin Pharma Inc., Delcath Systems Inc., Akorn Inc., and Insmed Inc. 10:19 a.m. Dec. 11, 2013 - PR Newswire
Stock Price Updates, and Charitable Contributions - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Dec. 4, 2013 - PR Newswire
Biotech Firms Participate in Upcoming Conferences; Sees Steady Numbers around Thanksgiving - Research Report on BioMarin, Halozyme, PDL BioPharma, Anika Therapeutics, and Exelis 8:00 a.m. Dec. 3, 2013 - PR Newswire
Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics 8:00 a.m. Nov. 26, 2013 - PR Newswire
Dan Spiegelman, CFO of BioMarin, to Present at the Deutsche Bank 2013 BioFest Conference in Boston 5:10 a.m. Nov. 26, 2013 - GlobeNewswire
FDA Approvals, Public Offerings and Stock Price Movements - Research Report on BioMarin, AEterna Zentaris, Charles River, Anika Therapeutics and Halozyme Therapeutics 8:00 a.m. Nov. 25, 2013 - PR Newswire
Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence, Prana, and Biostar 8:00 a.m. Nov. 20, 2013 - PR Newswire
FDA Advisory Committee Recommends Approval for BioMarin's Vimizim(TM) for the Treatment of Patients With Morquio A Syndrome 5:02 p.m. Nov. 19, 2013 - GlobeNewswire
BioMarin Stock Trading Halted Today 7:10 a.m. Nov. 19, 2013 - GlobeNewswire
FDA Posts Briefing Documents for Advisory Committee Meeting Reviewing Vimizim(TM) for the Treatment of Morquio A Syndrome 9:15 a.m. Nov. 15, 2013 - GlobeNewswire
Pre-Market Review: Delcath Systems Inc., BioMarin Pharma Inc., Insmed Inc., and Akorn Inc. 8:00 a.m. Nov. 15, 2013 - PR Newswire
BioMarin Announces French ATU Granted for Vimizim(TM) for the Treatment of Morquio A Syndrome 7:59 a.m. Nov. 15, 2013 - GlobeNewswire
Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data - Research Report on Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam 8:00 a.m. Nov. 8, 2013 - PR Newswire
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2013 Healthcare Conference 8:30 a.m. Nov. 5, 2013 - GlobeNewswire
Critical Alerts For Citigroup, Community Health, Oracle, Boeing, and BioMarin Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Nov. 1, 2013 - PR Newswire
Biotech Companies Report Quarterly Results - Research Report on Biogen Idec, Alexion, Medivation, BioMarin, and Dyax 9:00 a.m. Oct. 31, 2013 - PR Newswire
BioMarin Initiates Phase 3 Trial for BMN 673 for the Treatment of Metastatic gBRCA Breast Cancer 5:00 a.m. Oct. 31, 2013 - GlobeNewswire
Pre-Market Analysis: BioMarin Pharma Inc., Insmed Inc., Delcath Systems Inc., and Akorn Inc. 11:34 a.m. Oct. 25, 2013 - PR Newswire
BioMarin Announces Third Quarter 2013 Financial Results 5:33 p.m. Oct. 24, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...